Medical Marijuana, Inc. International Subsidiaries Achieve Best Revenue Month Ever in July 2021
10 Agosto 2021 - 10:03AM
InvestorsHub NewsWire
SAN DIEGO, CA -- August 10, 2021 -- InvestorsHub NewsWire
-- Medical
Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever
publicly traded cannabis company in the United States that launched
the world's first-ever cannabis-derived nutraceutical products,
brands and supply chain, announced today that the Company's
subsidiaries HempMeds®
Mexico and Kannaway®
Japan, as well as Medical Marijuana, Inc.'s third-party
manufacturing and distribution business, each achieved their
largest revenue months in their respective histories in July 2021.
Medical Marijuana, Inc. as a whole had its largest revenue month in
July since November 2020.
"Success is earned not acquired and I can confidently say that
our teams around the globe have been working harder than ever this
year to achieve financial and operational success milestones for
the company," said Medical Marijuana, Inc. CEO Blake Schroeder.
"For more than a decade, Medical Marijuana, Inc. has been a pioneer
and top-player in the cannabidiol (CBD) and hemp industries and our
recent accomplishments are a testament to the fact that we have no
intention of giving up on that reputation. We will become the first
truly global cannabis company and we are thankful for our customers
for helping us every step along the way."
Data leader Grand View Research recently reported that the CBD
market saw positive growth trends around the world in 2020 with
legal cannabis sales totaling $2.8 billion. Projections from Grand
View also show that the global CBD market is expected to grow at a
compound annual growth rate of 21.2% from 2021 to 2028 to reach
$13.4 billion by 2028.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct
business units in the non-psychoactive cannabinoid space: a global
portfolio of cannabinoid-based nutraceutical brands led by
Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality
legal non-psychoactive cannabis products derived from industrial
hemp; and a cannabinoid-based clinical research and botanical drug
development sector led by its pharmaceutical investment companies
and partners including AXIM® Biotechnologies, Inc. and
Neuropathix. Medical Marijuana, Inc. was named a top CBD producer
by CNBC. Medical Marijuana, Inc. was also the first company to
receive historic import permits for CBD products from the
governments of Brazil, Mexico, Argentina, and Paraguay and is a
leader in the development of international markets. The company's
flagship product Real Scientific Hemp Oil has been used in several
successful clinical studies throughout Mexico and Brazil to
understand its safety and efficacy.
Medical Marijuana, Inc.'s headquarters is in San Diego,
California, and additional information is available at
OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see
Medical Marijuana, Inc.'s corporate video, click here.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of Medical Marijuana, Inc. to
be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA)
DISCLOSURE
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products
that are in violation of the United States Controlled Substances
Act.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
Medical Marijuana (PK) (USOTC:MJNA)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Medical Marijuana (PK) (USOTC:MJNA)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024